Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Corbus Pharma (CRBP)

1.88   -0.34 (-15.32%) 03-05 08:22
Open: 2.15 Pre. Close: 2.22
High: 2.245 Low: 1.7701
Volume: 16,319,423 Market Cap: 158M
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.242 - 2.261 2.261 - 2.273
Low: 1.739 - 1.756 1.756 - 1.767
Close: 1.857 - 1.884 1.884 - 1.902

Technical analysis

as of: 2021-03-05 8:08:58 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.67     One year: 4.67
Support: Support1: 1.75    Support2: 1.46
Resistance: Resistance1: 3.14    Resistance2: 4.00
Pivot: 2.61
Moving Average: MA(5): 2.20     MA(20): 2.69
MA(100): 1.64     MA(250): 4.25
MACD: MACD(12,26): -0.01     Signal(9): 0.12
Stochastic oscillator: %K(14,3): 9.93     %D(3): 12.79
RSI: RSI(14): 37.11
52-week: High: 9.78  Low: 0.91  Change(%): -58.5
Average Vol(K): 3-Month: 1551885  10-Days: 1186296

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
CRBP has closed above bottom band by 2.8%. Bollinger Bands are 104% wider than normal. The large width of the bands suggest high volatility as compared to CRBP's normal range. The bands have been in this wide range for 6 bars. This is a sign that the current trend might continue.

Headline News

Thu, 04 Mar 2021
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Yahoo Finance

Mon, 01 Mar 2021
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sat, 27 Feb 2021
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expected to Post Quarterly Sales of $1.24 Million - MarketBeat

Fri, 26 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch

Wed, 17 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms market - MarketWatch

Tue, 16 Feb 2021
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, outperforms market - MarketWatch

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 84
Shares Float (M) 77
% Held by Insiders 1.73
% Held by Institutions 75.49
Shares Short (K) 16,250
Shares Short P. Month (K) 31,660

Stock Financials

EPS -1.784
EPS Est This Year -0.640
EPS Est Next Year -0.680
Book Value (p.s.) 0.360
Profit Margin
Operating Margin -2207.39
Return on Assets (ttm) -98.5
Return on Equity (ttm) -439.1
Qtrly Rev. Growth -52.5
Gross Profit (p.s.) -0.636
Sales Per Share 0.070
EBITDA (p.s.) -1.524
Qtrly Earnings Growth
Operating Cash Flow (M) -104
Levered Free Cash Flow (M) -58

Stock Valuations

PE Ratio -1.05
PEG Ratio
Price to Book value 5.22
Price to Sales 27.01
Price to Cash Flow -1.52

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.